Nasdaq:US$15.15 (+0.04) | HKEX:HK$24.10 (-0.10) | AIM:£2.41 (+0.03)
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Regulatory Notice | 6 Mar 2023

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Monday, March 6, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2022 annual results of HUTCHMED on February 28, 2023, the following awards granted under the Long Term Incentive Plan (“LTIP”) on April 20, 2020 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 3, 2023:-

 

Award Holders Number of American depositary shares (“ADS”)
Person Discharging Managerial Responsibilities
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) 50,431
Mr Johnny Cheng (Executive Director and Chief Financial Officer) 22,953
Total 73,384

 

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

  • Dr Weiguo Su

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name  Dr Weiguo Su
2 Reason for the notification
a) Position/status  Executive Director, Chief Executive Officer and Chief Scientific Officer
b) Initial notification/Amendment  Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name  HUTCHMED (China) Limited
b) LEI  2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 50,431 ADS
d) Aggregated information

Aggregated volume
Price
N/A
e) Date of the transaction  2023-03-03
f) Place of the transaction  Outside a trading venue

 

  • Mr Johnny Cheng

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name  Mr Johnny Cheng
2 Reason for the notification
a) Position/status  Executive Director and Chief Financial Officer
b) Initial notification/Amendment  Initial notification
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name  HUTCHMED (China) Limited
b) LEI  2138006X34YDQ6OBYE79
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)

Description of the financial instrument, type of instrument

Identification code

ADS each representing five Ordinary Shares of US$0.10

ADS ISIN: US44842L1035

b) Nature of the transaction Vesting of awards granted on April 20, 2020 under HUTCHMED’s LTIP
c) Price(s) and volume(s)
Price(s) Volume(s)
Nil 22,953 ADS
d) Aggregated information

Aggregated volume
Price
N/A
e) Date of the transaction  2023-03-03
f) Place of the transaction  Outside a trading venue

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has about 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/​immunology. Since inception HUTCHMED has been focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.